About
Poseidon LLC is a preclinical-stage company with a patented platform technology to develop novel therapeutics using a non-immunogenic protein modality.
Unlike conventional or bi-specific antibodies, their protein technology is developed to bind multiple targets on cancer cells to increase the valency and recruit immune cells as immune cell engagers (TCEs) to attack cancers. Poseidon LLC is particularly interested in the solid tumor space where most of the current drugs have failed to make an impact.
Also, in contrast to other biologics, the simplified design of their modality means that it can be produced in large quantities in a therapeutic ready format.
The challenge
As a young biotech in oncology, Poseidon LLC was searching for a more effective way of finding strategic partnerships to develop and bring their assets to market.
Like every out-licensor, Poseidon LLC was using traditional outreach methods such as going to conferences and partnering events, and email outreach where they had to adapt data sets and content every time based on the recipient profile. Poseidon shared the same pain points as most out-licensors when reaching out to large pharma: long waiting periods, difficulty contacting the appropriate person, conversations that end abruptly, and expensive travel costs to events.
At partnering events, aside from the serendipitous pitches to key people in corridors, it was difficult to book meetings with the target companies. Moreover, due to lack of continued conversations, even when they were able to capture interest, they would have to wait till next year, or the next conference, to showcase the development they have achieved for their asset. With budget and mobility constraints, it’s often very difficult to be present at all partnering events around the world.
Poseidon LLC was looking for a solution that can relieve some of the constraints of their current outreach methods with a high ROI. Ideally, they needed a solution where they could showcase their assets to in-licensors continuously, globally, and update them on developments in real-time.
Connecting with in-licensors seeking strategic partnerships
Our cutting-edge match making platform, Inpart Connect, serves as the backbone of a thriving network, uniting over 6,500 industry professionals, academic organizations, biotechs, pharma companies and investors.
Through Connect, we empower users to enhance their visibility, expedite partner discovery, and gain invaluable strategic insights.
Rajika Perera, Co-founder and CEO of Poseidon LLC met with Inpart’s representatives and was intrigued by the unique solution offered for connecting out-licensors with in-licensors seeking strategic innovation partnerships.
Poseidon LLC listed their assets on Inpart Connect as part of our pilot program for biotech in March 2023, matching them with our global network of over 2000 active biopharma companies across 60 countries. Our smart match making algorithm and team of STEM experts expedited their outreach process and brought unprecedented visibility to their listed assets.
Poseidon LLC found the onboarding process easy and intuitive, with our account managers guiding them through the process of filling in the information and setting up their profile on the platform with best practices in place. Poseidon LLC receives quarterly impact reports on the KPIs linked to their assets, including feedback, companies who viewed their assets, number of matches engaged, and much more.
Inpart’s account managers continue to guide and engage with Poseidon LLC on a regular basis to maximize their visibility and success with Inpart Connect. They are invited to participate in various marketing outreach programs in addition to being featured in monthly bulletins.
The result
Poseidon LLC proactively integrates the outreach led by their teams and outreach led by Inpart Connect.
- 4 assets listed
- 4 personalized feedback
- 1 introduction with an in-licensor
With the quarterly impact reports, they can identify the companies with the most interest and target their approach to connect with these companies at conferences, curating and sharing whitepapers based on their search.
“We find a lot of synergy with Inpart and have always seen them as a companion to what we want to achieve.”
Rajika PereraCo-founder & CEO
Inpart has facilitated matches with top pharma and smaller specialized pharma companies around the world that they would have never discovered outside of Inpart’s network.
“Inpart helped us reach all types of oncology in-licensors around the world, including small to medium sized pharma, that was not in our initial target, or we were clueless about. It would have been impossible for us to find this information on our own and conduct the outreach at this scale.”
Rajika PereraCo-founder & CEO
The always-accessible platform allows Poseidon LLC to communicate results of different developments in real-time by simply updating their assets on Connect. Their matches are automatically informed about these changes.
“It is not possible to be present at every partnering conference, as they are expensive. With Inpart’s help, we’re hoping to create enough visibility for our assets and make it easier for us to approach companies that have shown interest in the upcoming partnering events.”
Rajika PereraCo-founder & CEO
Since March 2023, Poseidon LLC has listed 4 assets and received 4 personalized feedback and 1 introduction with an in-licensor, over the period of 6 months.
“We were looking for more innovative ways to find funding. Inpart helped us get a lot of feedback on our new asset in a very short amount of time, including interest from the top 5 pharma companies. The feedback reassured us that we were on the right track, and we could provide updates in real-time using the platform, instead of waiting for next year’s conference.”
Rajika PereraCo-founder & CEO
